MARKET

TVGNW

TVGNW

Tevogen Bio
NASDAQ
0.0419
-0.0003
-0.71%
Closed 11:02 01/02 EST
OPEN
0.0416
PREV CLOSE
0.0422
HIGH
0.0419
LOW
0.0360
VOLUME
75.87K
TURNOVER
--
52 WEEK HIGH
0.1218
52 WEEK LOW
0.0301
MARKET CAP
--
P/E (TTM)
-0.1960
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TVGNW last week (1222-1226)?
Weekly Report · 12/29/2025 09:44
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
Barchart · 12/22/2025 11:40
Weekly Report: what happened at TVGNW last week (1215-1219)?
Weekly Report · 12/22/2025 09:44
Tevogen CEO Donates Personal Shares to Support Local Fire Department
Barchart · 12/19/2025 10:10
Weekly Report: what happened at TVGNW last week (1208-1212)?
Weekly Report · 12/15/2025 09:48
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
Barchart · 12/11/2025 14:15
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
Barchart · 12/09/2025 13:20
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
Barchart · 12/08/2025 13:50
More
About TVGNW
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.

Webull offers Tevogen Bio Holdings Inc stock information, including NASDAQ: TVGNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVGNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVGNW stock methods without spending real money on the virtual paper trading platform.